Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, Room M-1286, San Francisco, CA 94143-1270, USA.
Hematol Oncol Clin North Am. 2009 Dec;23(6):1213-21. doi: 10.1016/j.hoc.2009.08.004.
Data concerning the prevalence of chronic immune thrombocytopenia (ITP) among adults are limited and are confounded by lack of concordance of definitions of stage of disease. In the largest series of outpatients, prevalence has been estimated to range from 5.6 to 20 per 100,000 population and increases with advancing age. A female predominance is most pronounced among middle-aged patients, and no racial variation is apparent. Adult patients with chronic ITP may have a better prognosis than previously thought, although bleeding risk increases dramatically in association with severe thrombocytopenia and older age; a small minority of patients may recover spontaneously. More systematic analyses, with standardized definitions of cases and adequate duration of follow up, are needed.
关于成年人慢性免疫性血小板减少症 (ITP) 的患病率的数据有限,并且由于疾病阶段的定义不一致而受到混淆。在最大的一系列门诊患者中,患病率估计范围为每 10 万人中有 5.6 至 20 人,并且随着年龄的增长而增加。在中年患者中,女性优势最为明显,而且没有明显的种族差异。尽管与严重血小板减少症和年龄较大相关的出血风险急剧增加,但慢性 ITP 的成年患者的预后可能比以前认为的要好;少数患者可能会自发恢复。需要更系统的分析,包括对病例进行标准化定义和足够的随访时间。